The most important prognostic indicators to predict patient outcome in breast cancer are hormone receptor status, axillary lymph node status and histological grade; although these give a broad overview of outcome, they cannot predict for all patients. The recent development of cDNA array analysis provides the opportunity for a more refined approach based on molecular classification of individual tumours (see Additional information [1]). A previous study by the same authors identified molecular profiles in a cohort of nine benign and 72 malignant breast tumours (see Additional information [2]). The aim of this work was to use this technology to identify patients at increased risk of tumour recurrence. …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.